Adult Dosing
CMV retinitis in AIDS patients
- Induction: 900 mg PO bid x 21 days
- MAINT: 900 mg PO Daily
CMV prophylaxis, heart transplant
- 900 mg PO Daily
- Note: Start within 10 days of transplantation and continue until 100 days post-transplantation
CMV prophylaxis, kidney transplant
- 900 mg PO Daily
- Note: Start within 10 days of transplantation and continue until 200 days post-transplantation
CMV prophylaxis, kidney-pancreas transplant
- 900 mg PO Daily
- Note: Start within 10 days of transplantation and continue until 200 days post-transplantation
Pediatric Dosing
Prevention of CMV, heart transplant
Child (4 months-16 yrs)
- Dose: [7 x BSA x CrCl] PO Daily
- Max: 900 mg/day
- Note: Calculate BSA according to Mosteller formula and CrCl according to modified Schwartz formula. Start within 10 days of transplant and continue until 100 days post-transplant. Solution is preferred, but may use tablets if calculated dose is within 10% of available tablet strength of 450 mg. Round calculated dose to nearest 25 mg increment
Prevention of CMV, kidney transplant
Child (4 months-16 yrs)
- Dose: [7 x BSA x CrCl] PO Daily
- Max: 900 mg/day
- Note: Calculate BSA according to Mosteller formula and CrCl according to modified Schwartz formula. Start within 10 days of transplant and continue until 100 days post-transplant. Solution is preferred but may use tablets if calculated dose is within 10% of available tablet strength of 450 mg. Round calculated dose to nearest 25 mg increment
[Outline]
Renal Dose Adjustment (Based on CrCl)
Adults
- 40-59 mL/min: Induction: 450 mg bid x 21 days; Maintenance dose: 450 mg qd
- 25-39mL/min: Induction: 450 mg qd x 21 days; Maintenance dose: 450 mg every other day
- 10-24mL/min: induction: 450 mg every other day x 10; Maintenance dose: 450 mg twice weekly
- <10 mL/min: Avoid use
Child
- Use usual pediatric dose equation
Hepatic Dosing Adjustment
- Hepatic impairment: Dose adjustments not defined
See Supplemental Patient Information
- Safety and efficacy have not been established for the following conditions
- Prevention of CMV disease in solid organ transplants other than those indicated
- Prevention of CMV disease in pediatric solid organ transplant patients < 4 months of age
- Treatment of congenital CMV disease
- Valganciclovir is metabolized to ganciclovir; doses of valganciclovir and ganciclovir are not bioequivalent
- Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, and aplastic anemia have been reported with the use of valganciclovir or ganciclovir. Do not administer if absolute neutrophil count is < 500 cells/µL, platelet count is < 25,000/µL, or hemoglobin is < 8 g/dL. Monitor platelet and complete blood counts frequently
- Based on animal studies, vanganciclovir may cause temporary or permanent inhibition of spermatogenesis
- Women of childbearing potential should use effective contraception during and following treatment. Men should practice barrier contraception during and following treatment
- Acute renal failure may occur in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Monitor renal function
Cautions: Use cautiously in
- Renal impirment
- Pre-existing cytopenias
- Bone marrow depression
- Concomitant XRT
- Concomitant nephrotoxic drugs
- Elderly patients
- Dehydration
Supplemental Patient Information
- See instructions for oral solution administration and patient information supplied with product.
Pregnancy Category:C
Breastfeeding: Safety Unknown. Because of the potential for possible serious adverse reactions in nursing infants a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
Pricing data from www.DrugStore.com in U.S.A.
- Valcyte 450 MG TABS [Bottle] (GENENTECH)
60 mg = $2829.85
180 mg = $8427.78
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Valcyte 450 MG Oral Tablet
Ingredient(s): Valganciclovir
Imprint: VGC;450
Color(s): Pink
Shape: Oval
Size (mm): 17.00
Score: 0
Inactive Ingredient(s): cellulose, microcrystalline / povidone k30 / crospovidone / stearic acid / hypromellose / titanium dioxide / polyethylene glycol 400 / ferric oxide red / polysorbate 80
Drug Label Author:
Hoffmann-La Roche Inc
DEA Schedule:
Non-Scheduled
